Highest-materiality recent filing
ENvue Medical removes Series H Preferred Floor Price in exchange for $2.5M investment
Entered Amendment Agreement with Required Holders to file Certificate of Amendment removing Floor Price from Series H Convertible Preferred Stock.
NanoVibronix amends CEO contract with 9% equity grant; appoints interim CFO
CEO Doron Besser new base salary $360K, bonus up to $180K; severance of 12 months' base salary on change-of-control termination.
Christopher Fashek, Thomas Mika, Martin Goldstein, Brian Murphy retired immediately before the 2025 Annual Meeting for personal reasons; no disagreement with Company.
NanoVibronix to rebrand as ENvue Medical, focus on enteral-feeding navigation platform
ENvue feeding-tube placement system identified as core growth platform; 38 hospitals already using it.
NanoVibronix announces four directors will not stand for reelection at 2025 annual meeting
Christopher Fashek, Thomas Mika, Martin Goldstein, and Brian Murphy to retire from Board immediately prior to 2025 Annual Meeting.
NanoVibronix dismisses Zwick CPA, appoints E&Y as auditor; CFO Brown gets amended deal
Dismissed Zwick CPA PLLC; new auditor is Kost Forer Gabbay & Kasierer (E&Y) for FY2025.
NanoVibronix raises $8M in private placement of Series H convertible preferred and warrants
Initial closing of $8M gross proceeds: 8,889 Series H preferred shares ($1,000 stated value, convertible at $1.01/sh) and warrants for 4,678,363 shares at $2.25/sh.
NanoVibronix shareholders approve reverse stock split with 1:2 to 1:50 range
Reverse stock split amendment approved: ratio of 1-for-2 to 1-for-50, at Board discretion, within one year.
NanoVibronix raises $10M in public offering of Series G preferred and warrants
Gross proceeds ~$10M from 400,000 Series G convertible preferred shares at $25/share, each with a warrant to buy 4.9M common shares at $2.04.
the Board of Directors (the “ Board ”) of NanoVibronix, Inc. (the “ Company ”) appointed Doron Besser, M.D., a director of the Board and Chief Executive Officer and President of the Company’s wholly-owned subsidiary, ENvue Medical Holdings LLC (“ ENvue ”), as the Company’s Chief Executive Officer (“ CEO ”), effective as of the same date
Brian Murphy resigned from the Company as its CEO due to Mr. Murphy’s retirement, effective as of the same date.
Max materiality 0.75 · Median 0.57 · Most common event other_material